Top 40 Best-Selling Oncology Drugs in 2023 by 2022 Data
XTalks
FEBRUARY 5, 2024
PD-1 checkpoint inhibitors like Opdivo and Keytruda have been transformative in oncology, with Keytruda having had the edge due to having approvals in several more indications than Opdivo and strong clinical trial results, including as a first-line treatment in combination with chemotherapy. percent from 2021 to 2022 for Janssen.
Let's personalize your content